From Medscape Oncology

Coverage from the

American Association for Cancer Research (AACR) 2018 Annual Meeting

April 14 - 18, 2018; Chicago, Illinois

April 14 - 18, 2018 Chicago, Illinois

AACR 2018 Pembro Plus Chemo: Practice-Changing for mNSCLC Adding pembrolizumab to chemotherapy provided significant improvement in both overall and progression-free survival; the results have been hailed as practice-changing.
Medscape Medical News, April 17, 2018
AACR 2018 Successful CAR T-Cell Tx Needs Good T Cells to Begin With Starting with poor-quality T cells may be a key problem in the manufacturing of effective and functional CAR T cells, which may explain why it has been difficult to apply this approach to all cancers.
Medscape Medical News, March 20, 2018
AACR 2018 Improving Diversification of Cancer Patients in Clinical Trials Underserved populations experiencing cancer health disparities are underrepresented in clinical trials (CTs). AACR is taking the lead on fixing this disparity with its '2020 by 2020' initiative.
Medscape Medical News, March 20, 2018

Conference News

AACR 2018 Lorlatinib Addresses Resistance to ALK TKIs in NSCLC
Medscape Medical News, April 24, 2018
AACR 2018 Physical Activity Significantly Boosts Survival in Cancer Pts
Medscape Medical News, April 23, 2018
AACR 2018 Olaparib in Breast Cancer: PFS Is Significant but OS Is Not
Medscape Medical News, April 18, 2018
AACR 2018 Resistance to PD-1 Inhibition Overcome With a Combination
Medscape Medical News, April 18, 2018
AACR 2018 Neoadjuvant Nivolumab Shows Benefit in NSCLC
Medscape Medical News, April 17, 2018
AACR 2018 TMB as New Biomarker in NSCLC -- Ready for Clinic?
Medscape Medical News, April 17, 2018
AACR 2018 Pembro Plus Chemo: Practice-Changing for mNSCLC
Medscape Medical News, April 17, 2018

AACR 2018 BLU-667: New Hope for NSCLC and Medullary Thyroid Cancer
Medscape Medical News, April 16, 2018
AACR 2018 Nonchromosomal Birth Defects Linked With Childhood Cancers
Medscape Medical News, April 16, 2018
AACR 2018 Crizotinib: New Standard for ALK+ Myofibroblastic Tumor
Medscape Medical News, April 16, 2018
AACR 2018 Adjuvant Pembrolizumab for Melanoma -- Approval Imminent?
Medscape Medical News, April 16, 2018
AACR 2018 Successful CAR T-Cell Tx Needs Good T Cells to Begin With
Medscape Medical News, March 20, 2018
AACR 2018 Improving Diversification of Cancer Patients in Clinical Trials
Medscape Medical News, March 20, 2018
AACR 2018 Why Some Breast Cancer Becomes Resistant to Hormone Therapy
Medscape Medical News, March 20, 2018

Most Popular News from AACR 2017

Long-Term Aspirin May Cut Risk for Cancer Death Long-term, regular aspirin use was associated with a reduced relative risk for both death from any cause and from various cancers, in a big observational study.
Medscape Medical News, Apr 6, 2017
Rice Bran, Bean Powder Might Reduce Colorectal Cancer Risk Diet supplemented with high-fiber rice bran and navy bean powder produces beneficial changes in the gut that might reduce colorectal cancer risk over time.
Medscape Medical News, Apr 7, 2017
It's 'Wacky' but Improves Survival in Glioblastoma A device that uses electric 'tumor treating fields' to treat brain cancer is 'outside the box' but is also FDA-approved, and final phase 3 data are now available.
Medscape Medical News, Apr 3, 2017

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Perspectives

Adjuvant Immunotherapy Ups Recurrence-Free Survival in Melanoma
Jeffery S. Weber, MD, PhD
Dealing With Data Overload in Oncology
H. Jack West, MD; Hossein Borghaei, DO
Time to 'Rethink' Immunotherapy for Molecularly Driven NSCLC
H. Jack West, MD; Hossein Borghaei, DO
Trial 'Desperately Needed' to Sequence Immunotherapy and Chemo in Lung Cancer
H. Jack West, MD; Hossein Borghaei, DO
KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC
H. Jack West, MD; Hossein Borghaei, DO
Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients?
H. Jack West, MD; Hossein Borghaei, DO
Is This New Immunotherapy Biomarker Really 'Ready for Primetime'?
H. Jack West, MD; Hossein Borghaei, DO
KEYNOTE-189 Establishes New Lung Cancer Standard of Care
H. Jack West, MD; Hossein Borghaei, DO
Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Mark G. Kris, MD
Checkpoint Inhibitors Have a Role for 'Virtually Every Patient'
Mark G. Kris, MD
Interpreting KEYNOTE-189 and CheckMate-227 for Clinical Practice
H. Jack West

Previous Coverage

Related Resources

Lung Cancer News & Perspectives